Opdivo nivolumab: Additional Phase Ib data

Additional data from 107 Yervoy ipilimumab-naive advanced melanoma patients who were previously treated with 1-5 systemic therapies in the open-label, U.S. Phase Ib CA209-003 trial showed that 0.1, 0.3, 1, 3 and 10 mg/kg doses of IV Opdivo every 2 weeks for <96 weeks led to a 5-year overall survival (OS) rate of 34% with a median OS of 17.3 months at a minimum follow-up of 45 months. The 3 mg/kg dose of Opdivo led to a 5-year OS rate of 35% with a median OS of 20.3 months. The trial enrolled previously treated patients with melanoma, renal cell carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC) or colorectal cancer (CRC). Data were presented at the American Association for Cancer Research meeting in New Orleans. Bristol-Myers previously reported data from the trial (see BioCentury, May 21, 2012; June 3, 2013 & June 16, 2014). ...